With expanding use of highly effective CFTR modulatory therapy among younger patients with CF, including recent approval for elexacaftor/tezacaftor/ivacaftor for ages two and above, the natural history of the onset and progression of lung disease in young children is likely to change. This evidence concerns the gene CFTR and cystic fibrosis.